The FDA approves asundexian, the first factor XIa inhibitor, cutting stroke risk 26% and setting a regulatory benchmark for factor XI drug developers.
News|Articles|October 1, 2004
- Pharmaceutical Technology-10-01-2004
- Volume 2004 Supplement
- Issue 7
Validation of Sterile Filtration
This article discusses the basics of sterile filter qualification and validation, with emphasis on bacterial challenge protocol development and testing. Reference is made to Technical Report no. 26 of the Parenteral Drug Association.
Advertisement
Articles in this issue
about 22 years ago
Choosing the Proper Filterabout 22 years ago
Principles of Steam-In-Placeabout 22 years ago
Single-Use Technology for Sterilizing-Grade Filtrationabout 22 years ago
The Integrity Tests: Choosing Diffusive Airflows of Bubble PointsAdvertisement
Related to this article
Coverage from AAPS PharmSci 360 and CPHI Milan featured discussion about impurities, devices, and supply resilience. This week also included topics such as AI accountability, oral peptides, and new licensing deals.
No operator touches a CAR-T batch before demonstrating proficiency. Generative AI users should meet the same standard, and a higher one, because an AI error does not stay inside one batch.
The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
USP data show fewer US drug shortages but longer ones, averaging 5+ years. Drug shortages are an incentive problem, not a manufacturing mystery.
The pharmaceutical supply chain is a complex system with high stakes. USP provides insights on how it is helping industry navigate global disruptions and procurement issues.
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
Continuous overall equipment effectiveness can be used to pinpoint hidden downtime and process bottlenecks in real time.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
What the First Factor XIa Approval Means for Developers
2
France Remains One of Europe’s Leading Biotech Funding Hubs
3
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
4
Drapeau’s AI Deep Dive: Qualify the Reviewer Before the AI Goes Live
5